首页 > 最新文献

Texas Heart Institute Journal最新文献

英文 中文
Delayed Giant Pseudoaneurysm With Left-to-Right Shunt Following Postinfarct Ventricular Septal Perforation Repair. 梗死后室间隔穿孔修补术后伴有左向右分流的延迟性巨大假动脉瘤
IF 0.9 4区 医学 Pub Date : 2023-12-06 DOI: 10.14503/THIJ-23-8269
Yojiro Machii, Makoto Taoka, Yuki Hayashi, Atsushi Harada, Keita Kamata, Masashi Tanaka

Left ventricular pseudoaneurysm with a left-to-right shunt is extremely rare, requiring surgery if symptomatic; however, surgery has a high risk. Here, the case of a 77-year-old man with heart failure symptoms is reported, in which he develops a giant left ventricular pseudoaneurysm 16 months after ventricular septal perforation repair as a result of acute myocardial infarction, with mild shunt blood flow from the pseudoaneurysm to the right ventricle. Intraoperative findings showed a free wall rupture along the area where the patch was secured during the initial surgery. The patient was discharged on postoperative day 13, and postoperative examination revealed no abnormalities.

左心室假性动脉瘤伴左向右分流极为罕见,如果有症状则需要手术治疗,但手术风险很高。本文报告了一例 77 岁男性患者的病例,该患者因急性心肌梗死导致室间隔穿孔修补术,术后 16 个月出现巨大的左心室假性动脉瘤,假性动脉瘤向右心室轻度分流血流。术中发现,最初手术时固定补片的区域出现游离壁破裂。患者于术后第 13 天出院,术后检查未发现异常。
{"title":"Delayed Giant Pseudoaneurysm With Left-to-Right Shunt Following Postinfarct Ventricular Septal Perforation Repair.","authors":"Yojiro Machii, Makoto Taoka, Yuki Hayashi, Atsushi Harada, Keita Kamata, Masashi Tanaka","doi":"10.14503/THIJ-23-8269","DOIUrl":"10.14503/THIJ-23-8269","url":null,"abstract":"<p><p>Left ventricular pseudoaneurysm with a left-to-right shunt is extremely rare, requiring surgery if symptomatic; however, surgery has a high risk. Here, the case of a 77-year-old man with heart failure symptoms is reported, in which he develops a giant left ventricular pseudoaneurysm 16 months after ventricular septal perforation repair as a result of acute myocardial infarction, with mild shunt blood flow from the pseudoaneurysm to the right ventricle. Intraoperative findings showed a free wall rupture along the area where the patch was secured during the initial surgery. The patient was discharged on postoperative day 13, and postoperative examination revealed no abnormalities.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 6","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751473/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138812893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardioprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors and Their Possible Association With Normalization of the Circadian Index of Heart Rhythm. 钠-葡萄糖共转运体 2 抑制剂的心脏保护作用及其与心脏节律昼夜节律指数正常化的可能关系
IF 0.9 4区 医学 Pub Date : 2023-12-06 DOI: 10.14503/THIJ-23-8196
Nazile Bilgin Dogan, Hamiyet Yilmaz Yasar, Baris Kilicaslan

Background: Updated recommendations for the treatment of heart failure with reduced ejection fraction (HFrEF) include sodium-glucose cotransporter 2 (SGLT2) inhibitors and other long-established HFrEF therapies. These drugs' mechanisms of action have yet to be fully clarified.

Objective: This study evaluated the effects of SGLT2 inhibitors on the modulation of autonomic function at 1 month beyond conventional HF therapy.

Methods: This single-center, observational, prospective study was conducted from January 2020 to December 2022. Patients with type 2 diabetes who had ischemic HFrEF and met the study criteria were considered for SGLT2 inhibitor treatment with empagliflozin or dapagliflozin. Changes in the circadian index were used as the primary outcome to assess the early effects of SGLT2 inhibitors on autonomic function. Changes in functional effort capacity and laboratory findings were also evaluated. Participants' circadian index was measured by a 24-hour rhythm Holter monitoring recorder (BTL-08 Holter H100). A symptom-limited treadmill test assessed patients' effort capacities. Tests were repeated after 1 month of therapy.

Results: The mean (SD) age of the 151 participants was 56.95 (7.29) years; their mean (SD) left ventricular EF was 35.69% (7.10%), and 95 participants were men (62.9%). From baseline to 1 month, mean (SD) daytime heart rate (80.63 [9.17] vs 77.67 [8.04] beats per minute; P = .004) and nighttime heart rate (76.83 [11.34] vs 73.81 [10.25] beats per minute; P = .03) decreased significantly. Variation in the circadian indexes (mean [SD], 1.04 [0.02] vs 1.10 [0.04]; P < .001) was statistically significant, favoring increased modulation of autonomic function. The increases in exercise duration (mean [SD], 8.88 [3.69] minutes and median [IQR], 8.81 [5.76-12.13] minutes vs 9.72 [3.14] and 9.59 [7.24-12.22] minutes; P = .04) and exercise capacity (mean [SD], 203.38 [65.18] m and median [IQR], 119.22 [149.43-259.15] m vs 335.61 [51.39] and 325.79 [293.59-376.91] m; P < .001] were also significant.

Conclusion: The use of SGLT2 inhibitors during early treatment can favorably affect both autonomic dysfunction and functional effort capacity of patients with type 2 diabetes with ischemic HFrEF.

背景:射血分数降低型心力衰竭(HFrEF)治疗的最新建议包括钠-葡萄糖共转运体2(SGLT2)抑制剂和其他长期确立的HFrEF疗法。这些药物的作用机制尚未完全阐明:本研究评估了 SGLT2 抑制剂在常规高频治疗后 1 个月对自律神经功能调节的影响:这项单中心、观察性、前瞻性研究于 2020 年 1 月至 2022 年 12 月进行。符合研究标准的缺血性 HFrEF 2 型糖尿病患者被考虑接受恩格列净(empagliflozin)或达帕列净(dapagliflozin)的 SGLT2 抑制剂治疗。昼夜节律指数的变化是评估 SGLT2 抑制剂对自律神经功能早期影响的主要结果。此外,还评估了功能努力能力和实验室结果的变化。参与者的昼夜节律指数由 24 小时节律 Holter 监测记录仪(BTL-08 Holter H100)测量。症状有限的跑步机测试评估了患者的努力能力。治疗 1 个月后重复测试:151名参与者的平均(标清)年龄为56.95(7.29)岁;平均(标清)左心室EF为35.69%(7.10%),95名参与者为男性(62.9%)。从基线到 1 个月期间,平均(标清)日间心率(80.63 [9.17] vs 77.67 [8.04] 次/分钟;P = .004)和夜间心率(76.83 [11.34] vs 73.81 [10.25] 次/分钟;P = .03)显著下降。昼夜节律指数的变化(平均值 [SD], 1.04 [0.02] vs 1.10 [0.04];P < .001)具有统计学意义,表明自律神经功能的调节能力增强。运动持续时间(平均值 [SD], 8.88 [3.69] 分钟,中位数 [IQR], 8.81 [5.76-12.13] 分钟 vs 9.72 [3.14] 分钟和 9.59 [7.24-12.22] 分钟;P = .04)和运动能力(平均值[SD],203.38 [65.18] 米,中位数[IQR],119.22 [149.43-259.15] 米 vs 335.61 [51.39] 和 325.79 [293.59-376.91] 米;P < .001)也有显著差异:结论:在早期治疗期间使用 SGLT2 抑制剂可对缺血性 HFrEF 的 2 型糖尿病患者的自主神经功能障碍和功能努力能力产生有利影响。
{"title":"Cardioprotective Effects of Sodium-Glucose Cotransporter 2 Inhibitors and Their Possible Association With Normalization of the Circadian Index of Heart Rhythm.","authors":"Nazile Bilgin Dogan, Hamiyet Yilmaz Yasar, Baris Kilicaslan","doi":"10.14503/THIJ-23-8196","DOIUrl":"10.14503/THIJ-23-8196","url":null,"abstract":"<p><strong>Background: </strong>Updated recommendations for the treatment of heart failure with reduced ejection fraction (HFrEF) include sodium-glucose cotransporter 2 (SGLT2) inhibitors and other long-established HFrEF therapies. These drugs' mechanisms of action have yet to be fully clarified.</p><p><strong>Objective: </strong>This study evaluated the effects of SGLT2 inhibitors on the modulation of autonomic function at 1 month beyond conventional HF therapy.</p><p><strong>Methods: </strong>This single-center, observational, prospective study was conducted from January 2020 to December 2022. Patients with type 2 diabetes who had ischemic HFrEF and met the study criteria were considered for SGLT2 inhibitor treatment with empagliflozin or dapagliflozin. Changes in the circadian index were used as the primary outcome to assess the early effects of SGLT2 inhibitors on autonomic function. Changes in functional effort capacity and laboratory findings were also evaluated. Participants' circadian index was measured by a 24-hour rhythm Holter monitoring recorder (BTL-08 Holter H100). A symptom-limited treadmill test assessed patients' effort capacities. Tests were repeated after 1 month of therapy.</p><p><strong>Results: </strong>The mean (SD) age of the 151 participants was 56.95 (7.29) years; their mean (SD) left ventricular EF was 35.69% (7.10%), and 95 participants were men (62.9%). From baseline to 1 month, mean (SD) daytime heart rate (80.63 [9.17] vs 77.67 [8.04] beats per minute; P = .004) and nighttime heart rate (76.83 [11.34] vs 73.81 [10.25] beats per minute; P = .03) decreased significantly. Variation in the circadian indexes (mean [SD], 1.04 [0.02] vs 1.10 [0.04]; P < .001) was statistically significant, favoring increased modulation of autonomic function. The increases in exercise duration (mean [SD], 8.88 [3.69] minutes and median [IQR], 8.81 [5.76-12.13] minutes vs 9.72 [3.14] and 9.59 [7.24-12.22] minutes; P = .04) and exercise capacity (mean [SD], 203.38 [65.18] m and median [IQR], 119.22 [149.43-259.15] m vs 335.61 [51.39] and 325.79 [293.59-376.91] m; P < .001] were also significant.</p><p><strong>Conclusion: </strong>The use of SGLT2 inhibitors during early treatment can favorably affect both autonomic dysfunction and functional effort capacity of patients with type 2 diabetes with ischemic HFrEF.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 6","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-12-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751477/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138812891","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Left Main Coronary Artery and Bilateral Mammary Artery Aneurysms in a Patient With Extensive Aortopathy. 一名大动脉病变患者的左冠状动脉主干和双侧乳腺动脉瘤。
IF 0.9 4区 医学 Pub Date : 2023-12-04 DOI: 10.14503/THIJ-23-8248
Ala' Arafah, Richard Pham, Steven J Filby
{"title":"Left Main Coronary Artery and Bilateral Mammary Artery Aneurysms in a Patient With Extensive Aortopathy.","authors":"Ala' Arafah, Richard Pham, Steven J Filby","doi":"10.14503/THIJ-23-8248","DOIUrl":"10.14503/THIJ-23-8248","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 6","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751475/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138488806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The 2022 American College of Cardiology Expert Consensus on the Role of Nonstatin Therapies: An Expert-Guided Tour. 2022年美国心脏病学会关于非他汀类药物治疗作用的专家共识:专家指导之旅。
IF 0.9 4区 医学 Pub Date : 2023-11-17 DOI: 10.14503/THIJ-23-8233
Mini G Varughese, Christie M Ballantyne
{"title":"The 2022 American College of Cardiology Expert Consensus on the Role of Nonstatin Therapies: An Expert-Guided Tour.","authors":"Mini G Varughese, Christie M Ballantyne","doi":"10.14503/THIJ-23-8233","DOIUrl":"10.14503/THIJ-23-8233","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 6","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-11-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751478/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138446594","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subcutaneous vs Transvenous Implantable Cardioverter-Defibrillators: A Brief Review of the Current Landscape. 皮下与静脉植入式心脏复律除颤器:当前形势的简要回顾。
IF 0.9 4区 医学 Pub Date : 2023-11-06 DOI: 10.14503/THIJ-23-8145
Henry C Zheng, Hamid Afshar
{"title":"Subcutaneous vs Transvenous Implantable Cardioverter-Defibrillators: A Brief Review of the Current Landscape.","authors":"Henry C Zheng, Hamid Afshar","doi":"10.14503/THIJ-23-8145","DOIUrl":"10.14503/THIJ-23-8145","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 6","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751471/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71522978","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Established and Emerging Device Therapy in Heart Failure: Cardiac Contractility Modulation. 已建立和新兴的心力衰竭设备治疗:心脏收缩调节。
IF 0.9 4区 医学 Pub Date : 2023-11-02 DOI: 10.14503/THIJ-23-8184
Justin Haloot, Mihail G Chelu
{"title":"Established and Emerging Device Therapy in Heart Failure: Cardiac Contractility Modulation.","authors":"Justin Haloot, Mihail G Chelu","doi":"10.14503/THIJ-23-8184","DOIUrl":"10.14503/THIJ-23-8184","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 6","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-11-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751469/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71487672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence, Risk Score Performance, and In-Hospital Outcomes of Postoperative Atrial Fibrillation After Cardiac Surgery. 心脏手术后心房颤动的发生率、风险评分表现和住院结果。
IF 0.9 4区 医学 Pub Date : 2023-10-25 DOI: 10.14503/THIJ-23-8221
Matthew W Segar, Alexander Marzec, Mehdi Razavi, Karen Mullins, Joanna E Molina-Razavi, Subhasis Chatterjee, Alexis E Shafii, Jennifer R Cozart, Marc R Moon, Abdi Rasekh, Mohammad Saeed

Background: Postoperative atrial fibrillation (POAF) frequently complicates cardiac surgery. Predicting POAF can guide interventions to prevent its onset. This study assessed the incidence, risk factors, and related adverse outcomes of POAF after cardiac surgery.

Methods: A cohort of 1,606 patients undergoing cardiac surgery at a tertiary referral center was analyzed. Postoperative AF was defined based on the Society of Thoracic Surgeons' criteria: AF/atrial flutter after operating room exit that either lasted longer than 1 hour or required medical or procedural intervention. Risk factors for POAF were evaluated, and the performance of established risk scores (POAF, HATCH, COM-AF, CHA2DS2-VASc, and Society of Thoracic Surgeons risk scores) in predicting POAF was assessed using discrimination (area under the receiver operator characteristics curve) analysis. The association of POAF with secondary outcomes, including length of hospital stay, ventilator time, and discharge to rehabilitation facilities, was evaluated using adjusted linear and logistic regression models.

Results: The incidence of POAF was 32.2% (n = 517). Patients who developed POAF were older, had traditional cardiovascular risk factors and higher Society of Thoracic Surgeons risk scores, and often underwent valve surgery. The POAF risk score demonstrated the highest area under the receiver operator characteristics curve (0.65), but risk scores generally underperformed. Postoperative AF was associated with extended hospital stays, longer ventilator use, and higher likelihood of discharge to rehabilitation facilities (odds ratio, 2.30; 95% CI, 1.73-3.08).

Conclusion: This study observed a high incidence of POAF following cardiac surgery and its association with increased morbidity and resource utilization. Accurate POAF prediction remains elusive, emphasizing the need for better risk-prediction methods and tailored interventions to diminish the effect of POAF on patient outcomes.

背景:术后心房颤动(POAF)经常使心脏手术复杂化。预测POAF可以指导预防其发作的干预措施。本研究评估了心脏手术后POAF的发生率、危险因素和相关不良后果。方法:对1606名在三级转诊中心接受心脏手术的患者进行队列分析。术后房颤是根据胸科医生协会的标准定义的:手术室退出后持续时间超过1小时或需要医疗或程序干预的房颤/房扑。评估了POAF的风险因素,并使用判别(受试者-操作者特征曲线下面积)分析评估了已建立的风险评分(POAF、HATCH、COM-AF、CHA2DS2-VASc和胸科医生协会风险评分)在预测POAF中的表现。使用调整后的线性和逻辑回归模型评估POAF与次要结果的相关性,包括住院时间、呼吸机时间和出院到康复机构。结果:POAF的发生率为32.2%(n=517)。发生POAF的患者年龄较大,有传统的心血管风险因素和较高的胸科医生学会风险评分,经常接受瓣膜手术。POAF风险评分显示受试者-操作员特征曲线下的区域最高(0.65),但风险评分通常表现不佳。术后房颤与住院时间延长、呼吸机使用时间延长和出院到康复机构的可能性增加有关(比值比,2.30;95%可信区间,1.73-3.08)。结论:本研究观察到心脏手术后POAF的发病率很高,并与发病率和资源利用率的增加有关。准确的POAF预测仍然难以捉摸,强调需要更好的风险预测方法和量身定制的干预措施来减少POAF对患者预后的影响。
{"title":"Incidence, Risk Score Performance, and In-Hospital Outcomes of Postoperative Atrial Fibrillation After Cardiac Surgery.","authors":"Matthew W Segar, Alexander Marzec, Mehdi Razavi, Karen Mullins, Joanna E Molina-Razavi, Subhasis Chatterjee, Alexis E Shafii, Jennifer R Cozart, Marc R Moon, Abdi Rasekh, Mohammad Saeed","doi":"10.14503/THIJ-23-8221","DOIUrl":"10.14503/THIJ-23-8221","url":null,"abstract":"<p><strong>Background: </strong>Postoperative atrial fibrillation (POAF) frequently complicates cardiac surgery. Predicting POAF can guide interventions to prevent its onset. This study assessed the incidence, risk factors, and related adverse outcomes of POAF after cardiac surgery.</p><p><strong>Methods: </strong>A cohort of 1,606 patients undergoing cardiac surgery at a tertiary referral center was analyzed. Postoperative AF was defined based on the Society of Thoracic Surgeons' criteria: AF/atrial flutter after operating room exit that either lasted longer than 1 hour or required medical or procedural intervention. Risk factors for POAF were evaluated, and the performance of established risk scores (POAF, HATCH, COM-AF, CHA2DS2-VASc, and Society of Thoracic Surgeons risk scores) in predicting POAF was assessed using discrimination (area under the receiver operator characteristics curve) analysis. The association of POAF with secondary outcomes, including length of hospital stay, ventilator time, and discharge to rehabilitation facilities, was evaluated using adjusted linear and logistic regression models.</p><p><strong>Results: </strong>The incidence of POAF was 32.2% (n = 517). Patients who developed POAF were older, had traditional cardiovascular risk factors and higher Society of Thoracic Surgeons risk scores, and often underwent valve surgery. The POAF risk score demonstrated the highest area under the receiver operator characteristics curve (0.65), but risk scores generally underperformed. Postoperative AF was associated with extended hospital stays, longer ventilator use, and higher likelihood of discharge to rehabilitation facilities (odds ratio, 2.30; 95% CI, 1.73-3.08).</p><p><strong>Conclusion: </strong>This study observed a high incidence of POAF following cardiac surgery and its association with increased morbidity and resource utilization. Accurate POAF prediction remains elusive, emphasizing the need for better risk-prediction methods and tailored interventions to diminish the effect of POAF on patient outcomes.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658140/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54231767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Optimized Catheter System Demonstrates Utility for Endomyocardial Delivery of Cardiopoietic Stem Cells in Target Patients With Heart Failure. 优化的导管系统证明了在心力衰竭靶向患者心肌内输送造血干细胞的实用性。
IF 0.9 4区 医学 Pub Date : 2023-10-23 DOI: 10.14503/THIJ-23-8247
Jozef Bartunek, Andre Terzic
{"title":"Optimized Catheter System Demonstrates Utility for Endomyocardial Delivery of Cardiopoietic Stem Cells in Target Patients With Heart Failure.","authors":"Jozef Bartunek, Andre Terzic","doi":"10.14503/THIJ-23-8247","DOIUrl":"10.14503/THIJ-23-8247","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658137/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50163319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The CardiAMP Cell Therapy for Heart Failure trial. CardiAMP细胞治疗心力衰竭试验。
IF 0.9 4区 医学 Pub Date : 2023-10-23 DOI: 10.14503/THIJ-23-8242
Carl J Pepine, Amish N Raval
{"title":"The CardiAMP Cell Therapy for Heart Failure trial.","authors":"Carl J Pepine, Amish N Raval","doi":"10.14503/THIJ-23-8242","DOIUrl":"10.14503/THIJ-23-8242","url":null,"abstract":"","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658138/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"50163320","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
ST-Segment Elevation Myocardial Infarction and Bleeding Complications in JAK2-Negative Polycythemia. JAK2阴性红细胞增多症ST段抬高心肌梗死和出血并发症。
IF 0.9 4区 医学 Pub Date : 2023-10-20 DOI: 10.14503/THIJ-23-8148
Priscilla Duran Luciano, Vanessa Sabella-Jiménez

Thrombotic and bleeding complications are major causes of morbidity and mortality in patients with polycythemia vera, who predominantly present with an alteration in the JAK2 gene. Because of their hypercoagulable state and risk of hemorrhage, patients with polycythemia vera who present with an acute myocardial infarction pose a challenge to physicians. This case report describes the presentation and treatment of a Hispanic patient with JAK2 V617F-negative primary polycythemia who developed cardiac arrest and ST-segment elevation myocardial infarction owing to complete occlusion of the left anterior descending artery as well as bleeding complications and postmyocardial pericarditis.

血栓和出血并发症是真性红细胞增多症患者发病率和死亡率的主要原因,这些患者主要表现为JAK2基因的改变。由于其高凝状态和出血风险,出现急性心肌梗死的真性红细胞增多症患者对医生构成了挑战。本病例报告描述了一名患有JAK2 V617F阴性原发性红细胞增多症的西班牙裔患者的表现和治疗,该患者因左前降支完全闭塞、出血并发症和心肌后心包炎而出现心脏骤停和ST段抬高心肌梗死。
{"title":"ST-Segment Elevation Myocardial Infarction and Bleeding Complications in JAK2-Negative Polycythemia.","authors":"Priscilla Duran Luciano, Vanessa Sabella-Jiménez","doi":"10.14503/THIJ-23-8148","DOIUrl":"10.14503/THIJ-23-8148","url":null,"abstract":"<p><p>Thrombotic and bleeding complications are major causes of morbidity and mortality in patients with polycythemia vera, who predominantly present with an alteration in the JAK2 gene. Because of their hypercoagulable state and risk of hemorrhage, patients with polycythemia vera who present with an acute myocardial infarction pose a challenge to physicians. This case report describes the presentation and treatment of a Hispanic patient with JAK2 V617F-negative primary polycythemia who developed cardiac arrest and ST-segment elevation myocardial infarction owing to complete occlusion of the left anterior descending artery as well as bleeding complications and postmyocardial pericarditis.</p>","PeriodicalId":48680,"journal":{"name":"Texas Heart Institute Journal","volume":"50 5","pages":""},"PeriodicalIF":0.9,"publicationDate":"2023-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658142/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49693157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Texas Heart Institute Journal
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1